Lakewood-Amedex Biotherapeutics Inc. Debt Instrument Issued Principal
Lakewood-Amedex Biotherapeutics Inc. (LABT) reported Debt Instrument Issued Principal of $1.50 million for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-18.
Financial Statements › Notes
us-gaap:DebtInstrumentIssuedPrincipal · last filed 2026-09-18
| Period end | Debt Instrument Issued Principal 12 month |
|---|---|
| 2025-12-31 | $1.50M S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B |